Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast

MT Newswires Live

Jul 10

Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.

Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.

The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2650907896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650907896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650907896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650907896","market":"nz","top_or_hot":-1,"title":"Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.</p><p>Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.</p><p>The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 14:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.</p><p>Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.</p><p>The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650907896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650907896","pubTimestamp":1783665422,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited","MSC":"新濠影汇"},"translate_title":"Mesoblast 第四财季 MSC Therapy 产品销售净收入超出 Jefferies 预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5,"MSC":1.5},"content_text":"Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}